Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This guy did not help out the CBD industry today:
https://www.msn.com/en-ca/video/money/there-is-no-evidence-of-cbd-benefits-says-former-fda-commissioner/vi-BBVQRL8
So many people I run across in business and personal know nothing about CBD. I think we are golden with these companies. When people catch on look out!
Nice pull back entry point on this today.
Outside market influences seemed to be under control...I was worried about Brexit but that is undercontrol...Also qe have more states signing hemps laws weekly
I hope you’re right!
This stock want 20$ im buying more in the am
ELLXF looks like a prime candidate for M&A.
Good read. Brief mention of Elixinol and Charlotte's Web.
https://www.forbes.com/sites/alanjbrochstein/2019/04/07/mergers-and-acquisitions-light-up-the-cannabis-sector/#5b040f4887e4
I loaded more at 3.85 this stock will continue up.
I like the cooling off. No doubts that this will take and hold the $4's
Lol I briefly invested in “other rival” a few months back hoping that it would get pumped and I could make a short-term profit. I sold the day before it hit $7 because it was all too shady for me. I’d say that “other rival” is one of the most likely stocks of the cannabis boom to be engaging in some fraudulent activities...
If we beat the other rival that is 5.75 i will lmfao...All those guys will be pissed lol...ellxf
ELLXF vs VFRM(cbd products comparisons)
1)ELLXF and VFRM are CBD/Hemp stocks
2)ELLXF= $4.22 per shrare
3)VFRM= $0.89 per share(less than $1. per share)
4)ELLXF products are NOT in CVS stores.
5)VFRM CBD products are in CVS stores.
6)VFRM operates a 140-acre farm and production facilities in Pueblo, Colorado, U.S.A.
Veritas Farms™ brand products can be found at several leading online and brick-and-mortar retailers across the United States, including select CVS Pharmacy stores.
This thing just opens up and trades sideways everyday. pretty remarkable.. still holding my early entries, but may let go some of my higher purchases. We’ll see. So far though so good, and super hot sector too. So why not
Great start to the week in Australia. Look slike we could break and hold the $4s this week.
Australian listing, EXL, up ~10%. How far can we go?
Can't go wrong with either one and it's amazing how many articles mention both of them..the class of the pack, IMO.
I can’t wait for the day that this pps is where Cweb is now.
CW and Ellxf are the 2 I like.
Excellent article thanks for sharing! I liked the end where they said if you want to try it buy the #1 CW!
Excellent article: Fake CBD – How to Tell if CBD Oil is Real or Fake
https://www.nanalyze.com/2019/03/fake-cbd-oil-real-fake/
Could’ve would’ve should’ve life is full of them GLTU
I wish I could go back in time and tell myself to buy MORE at 2.50! Go baby go!
And without any news. Sweet.
New 52wk high.. First hit @4 !!!
Dazed and confused: States push for legal clarity on CBD
https://www.kcra.com/article/dazed-confused-states-push-for-legal-clarity-on-cbd-cannabis/27047306
AP Updated: 1:53 PM PDT Apr 4, 2019
By PAUL ELIAS/Associated Press
SOURCE: KCRA
SAN FRANCISCO (AP) —
CBD oil-infused gummy bears, lattes and other food, drinks and dietary supplements are selling quickly even though the U.S. government says they're illegal and local authorities have forced some retailers to pull products. The confusion has the nation's two largest states and others moving to legalize the cannabis compound that many see as beneficial to their health.
Lawmakers in Texas and California are often in opposition, but they're both pushing bipartisan legislation to sidestep federal law and allow sales of the compound found in hemp and marijuana. Republicans and Democrats in Congress also are urging the U.S. Food and Drug Administration to change its stance.
Advertisement
The FDA announced Tuesday that it will hold a public hearing in May to gather more information.
Resolving the confusion can't come quick enough for Jonathan Eppers, who makes Vybes, a popular CBD oil-infused beverage. California health inspectors raided his Los Angeles warehouse in January and impounded $100,000 worth of the drink.
Eppers said about 50 California retailers have since dropped his product and he's moved production to Texas. He estimates lost sales, legal costs and relocation expenses have cost him at least $500,000.
"What is going on is unbelievable and asinine," Eppers said. "They put us in this state of limbo that's costing us."
Eppers and CBD fans are mystified by the legal insecurity. After all, they say, retailers in California and nine other states that have broadly legalized marijuana sell edibles and other products that get people high, though pot is illegal under federal law. U.S. officials generally have taken a hands-off approach in states where pot is legal.
The FDA has oversight of CBD because it is the active ingredient in an approved prescription drug to treat two rare seizure disorders. The agency says CBD can't be added to food or sold as a dietary supplement because officials haven't determined if it's safe or effective for other conditions.
FDA Commissioner Scott Gottlieb told Congress last week that enforcement is being limited to sellers who make false health claims. He says the agency recently sent warning letters to three companies touting CBD as a treatment for cancer, Alzheimer's disease, fibromyalgia and drug addiction.
"But there are products on the market right now that, given our enforcement priorities and our limited resources, we haven't taken action against," he said.
Sellers and users say CBD helps with pain, anxiety and inflammation, though limited scientific research supports those claims. It's turning up in products ranging from lotions, cosmetics and soap to diet pills, juices, cocktails, candy and drinks.
Short for cannabidiol, CBD is a non-psychoactive molecule found in hemp and marijuana. Both are cannabis plants, but only marijuana has enough of the compound THC to get users high. CBD oil is extracted when the plant is processed. While hemp derivatives are essentially THC-free, CBD oil from marijuana may have very little or enough to produce a high.
State and local officials are taking nearly all the enforcement actions against CBD. Health officials in California, which has the nation's largest marijuana marketplace, warned retailers last summer that anything edible containing CBD is illegal until lawmakers or regulators say otherwise.
The warning was largely ignored until early 2019, when state and local health officials began forcing some small businesses to pull products after receiving complaints.
San Francisco health officials recently barred two small operators from selling CBD-infused food and drink, while authorities in rural Grass Valley, 140 miles away, did the same to a small, cooperatively owned grocery store.
"It caught us way off guard," said Gus Dabais, owner of Sidewalk Wellness, one of the stores targeted.
The San Francisco Health Department sent warning letters to 1,900 businesses last year, spokeswoman Veronica Vien said. She said inspectors are not looking for CBD but responding to complaints.
She said that's how they ended up "red tagging" products at Dabais' business and Steap Tea Bar, a popular Chinatown stop that sold CBD-infused bubble tea.
Similar scenarios are playing out in Ohio, where authorities in January ordered a Cincinnati grocery store to remove CBD from two outlets. The following month, New York City health inspectors removed CBD products from a number of restaurants. Police in March raided two Fort Worth, Texas, retailers and seized CBD products after the local district attorney declared the compound illegal.
In Texas, one of a handful of states that outlaws all forms of marijuana, lawmakers are pushing a measure that would legalize hemp oil-infused edibles. It sailed through its first committee in the House this week.
In California, a similar CBD measure has moved on to the full Assembly.
"A number of people have been using it for years, and you can find it on retail shelves all over the place, but now people are surprised to find it's against the law," said Assemblywoman Cecilia Aguiar-Curry, a Napa-area Democrat who introduced the measure. "What this bill will do is clear up the confusion."
She said the legislation would stop state and local enforcement of the FDA's ban and hopes it becomes law by August.
"This would lift a legal cloud from a legitimate California business," said Jim Gross of the U.S. Hemp Roundtable, an industry association.
A growing number of federal lawmakers, including Senate Majority Leader Mitch McConnell and Democratic Sen. Ron Wyden of Oregon, are urging the FDA to approve CBD. They backed a measure taking hemp off the U.S. government's list of banned substances.
"Hemp is a versatile crop with many uses and applications," McConnell and Wyden wrote to the FDA in February. "We are hopeful that by working with you on the implementation of our legislation, we can help ensure that hemp can be a new cash crop for farmers across the country."
Follow this story to get instant e-mail alerts from KCRA on the latest developments and related topics.
Might be a dumb question, but is converting the ASX offering's price from AUD to USD a fair way to estimate the way the OTC offering will move the next day? EXL currently up .35, or 7.14%, to 5.25--which converts to 3.74 USD.
Found it
It is up in APRIL
DESCRIPTION
Elixinol Global Ltd. engages in the industrial hemp and medical cannabis business in Australia.
It manufactures and distributes industrial hemp-based dietary supplements, foods, and skincare products in the USA.DESCRIPTION
Elixinol Global Ltd. engages in the industrial hemp and medical cannabis business in Australia.
It manufactures and distributes industrial hemp-based dietary supplements, foods, and skincare products in the USA.
Streetwise Reports Examines Best-of-Breed Hemp/CBD Producers
GlobeNewswire•April 3, 2019
https://finance.yahoo.com/news/streetwise-reports-examines-best-breed-110000634.htmlSAN FRANCISCO, April 03, 2019 (GLOBE NEWSWIRE) -- Fincom Investment Partners surveys the hemp-CBD landscape and discusses two companies it believes are "best of breed."
Company mentioned: Elixinol Global Ltd. (EXL:ASX; ELLXF:OTCQX)
The hemp/CBD phenomena grows. Investors appear to be catching on. Our universe of publicly traded CBD "pure-plays" suggests the two "best-of-breed."
Charlotte's Web Holdings Inc. and Elixinol Global Ltd. are pioneers in hemp/CBD. Both are fast growers. Elixinol, the fastest over the second half of 2018, has new, cutting-edge products and a lower relative valuation. This balances with Charlotte's Web's stronger name recognition and larger retail sales base. Charlotte's Web's Q4 sales rebounded after a hiccup in Q3 and had solid Q/Q sales growth of 21%. Both companies have positive EBITDA, which must be a shock to cannabis investors, with what we believe is a superior business model to cannabis growers. (Disclosure: A director of Fincom Investment Partners is a long-time Charlotte's Web reseller).
We continue to suggest fair valuation for Elixinol remains one-half of Charlotte's Web's—discounted 20%. Charlotte's Web's sales are more than 2X.
Elixinol's 2018 sales were US$26 million, up 121% annually. Charlotte's Web's were $69 million, up 74% annually. Much of Elixinol sales are in lower margin private label, which becomes a strategic advantage since neither Charlotte's Web nor CV Sciences can boast significant experience with private label, third party or bulk CBD sales. Elixinol, perhaps, has a "leg up" on branded partnerships, building the "powered by Elixinol" brand—the brand behind the brands. We believe this is a stronger competitive "moat" than just selling through fickle retailers.
We have long argued CBD (the cannabidiols, a non-intoxicant) is a larger market—and a better investment—than cannabis.
Continue reading this article: Best-of-Breed Hemp/CBD Producers
hi there, great read; $ELLXF
just got on; Elixinol Global Limited (ASX: EXL; - n.y.s.e.'Elixinol Global Ltd. (ELLXF)'
NEW YORK, Sept. 18, 2018 /PRNewswire/ -- OTC Markets Group Inc.
(OTCQX: OTCM), operator of financial markets for 10,000 U.S. and
global securities, today announced Elixinol Global Limited (ASX: EXL;
Couldn't agree more, ANIA77. ELLXF $5.15 on ASX.
This is a must read for whoever wondering if CBD is better place to invest than MJ stocks..
I invest solely based on numbers. I always analyze financial reports and particularly look for good margins and profitability.. and CBD companies are unbeatable when it comes to that and this article proves it.
Great info. Thanks for sharing
This is why we are all in CBD... we have another gap up again today.. this what you get when stock is so thin.
Got it - thanks!
CAMPAIGN TO EDUCATE MEDIA ABOUT FDA’S PLAN FOR CBD
HERE IS WHAT THE MEDIA ISN’T REPORTING ON THE FDA AND CBD
This is a timestamped clip of an interview with FDA Commissioner Dr. Scott Gottlieb at the Brookings Institute on 3/19/19
You only need to watch it for 2 minutes to get the complete gist of what the FDA is going to do with CBD in 2019
It begins at 30:25 and you can stop listening at 32:30
Good info on explosive CBD market metrics compared to THC
https://grizzle.com/the-untapped-potential-of-cannabidiol-cbd/?ck_subscriber_id=295616597
The THC Market will Ultimately be Less Than Half the Size of the CBD Market
The THC market may be the first target for licensed producers because demand is more easily defined, but longer term the CBD market is where the real money is.
According to Canadian government estimates, recreational and medical cannabis demand could reach $10 billion in the first year of legalization.
But according to cannabis industry analysts The Brightfield Group, the hemp CBD market could be generating $22 billion a year by 2022.
Grizzle thinks this number is conservative.
In only four years the medically driven CBD market will be at least twice the size of the market for recreational cannabis.
CBD Pricing Compares Favourably to THC
To truly understand the economics of cannabis vs. hemp we have to compare the pure active ingredients only and exclude the parts of the flower that have no health or psychoactive qualities.
Consumption of cannabis flower is decreasing rapidly in favour of oils and vapes and the industry will soon be pricing cannabis products based on weight of active ingredient only, excluding the rest of the cannabis plant.
For example, when you’re quoted $10 per gram for flower at a legal dispensary, the flower by weight only contains 20% pure THC, so you are actually paying $50 per gram of THC.
Growing Costs /gram Wholesale /Gram Retail /Gram
Pure CBD Concentrate $0.08 $6.50 $97
Pure THC Concentrate $16.00 $40.00 $100
Dried CBD Flower $0.002 $0.16 $1.40
Dried THC Flower $2.00 $4.00 $7.50
Retail
Medically licensed cannabis oil from the 6 largest licensed producers sells for $100 per gram of THC on average.
CBD oil sells for a very similar price at $97 per gram of pure CBD.
In the US, Charlotte’s Web, a Colorado-based hemp grower, cultivates their own proprietary strain of hemp from which they extract, process, and distribute CBD-based products.
Their isolates sell for as high as $220 per gram of CBD but most products range from $32-$111, slightly lower than prices in Canada.
Wholesale
If we look at wholesale prices there is more of a difference. 100% pure THC cannabis oil sells for $40,000 per kg while CBD hemp oil only sells for $6,500 per kg.
The difference in market prices are at least partially explained by the big differences in growing costs which we explore below.
Growing Costs for CBD from Hemp are Far Lower than for THC
Based on extensive data from farms in Alberta, the cost of growing hemp is $400-$500 per acre or less than a cent per gram of hemp.
The cost of producing 100% pure CBD oil, which is much more concentrated, only increases growing costs to $0.07 per gram.
In contrast, licensed producers grow THC-rich flower for $1.00-$3.00 per dry gram with the extra flower required to produce a gram of pure THC pushing the cost up to $16.00, 200x more costly than growing hemp.
Hemp Growing Costs per Acre
Source: Alberta Agriculture and Forestry
CBD Demand Per Person Could be 3x-10x Higher Than THC
In the future, the average CBD user could be spending double or triple what the average Canadian spends on THC-rich cannabis today.
A powerful driver of CBD profitability is the increased consumption per person compared to psychoactive THC.
CBD lacks the intoxicating effects of THC allowing a much higher dose to be taken with no serious side effects.
According to Yasmin Hurd, an experienced CBD researcher, doses of 200mg of CBD or more are needed to achieve real health benefits, compared to 5mg to achieve a satisfactory effect for THC.
Product labels and online medical marijuana resources such as Greenrelief.ca and CanniMed Therapeutics confirm the difference in dosing, with a starting dose for CBD at 10-25 milligrams while a starting dose of THC is only 1-5 milligrams.
The average medical marijuana user in Canada spends $3-$6 a day on cannabis flower or oil according to Health Canada data, which means the average CBD user could be spending 3x-7x more, or up to $10,000 a year at current prices.
CBD oil could be a very lucrative new segment for the legal market.
Potential Revenue Opportunity 7x Higher with CBD
THC Oil CBD Oil
mg Consumed per Day 56 200
Grams per Year 20 73
Retail Price per Gram $50 $97
Yearly Revenue Per Person $1,018 $7,060
EXL. If you click the link in my last post, you can follow Elixinol on the Australian Exchange.
What's the ticker symbol for this on ASX please?
ELLXF up 4.5% on ASX last night.
Might be able to break through $5.00 tonight.
https://www.elixinolglobal.com/site/investor/investor-centre-home
Best-of-Breed Hemp/CBD Producers ELLXF/CWBHF
http://www.streetwisereports.com/article/2019/04/02/best-of-breed-hemp-cbd-producers.html
Fincom Investment Partners surveys the hemp-CBD landscape and discusses two companies it believes are "best of breed."
CBD
Hemp/CBD heats up. Wall Street catches on.
Next wave begins: CVS Pharmacy and Walgreens sell CBD.
The hemp/CBD phenomena grows. Investors appear to be catching on. Our universe of publicly traded CBD "pure-plays" suggests the two "best-of-breed."
Charlotte's Web Holdings Inc. (CWEB:CSE: CWBHF:OTCQX) (CWEB) and Elixinol Global Ltd. (EXL:ASX; ELLXF:OTCQX) are pioneers in hemp/CBD. Both are fast growers. Elixinol, the fastest over the second half of 2018, has new, cutting-edge products and a lower relative valuation. This balances with CWEB's stronger name recognition and larger retail sales base. CWEB's Q4 sales rebounded after a hiccup in Q3 and had solid Q/Q sales growth of 21%. Both companies have positive EDITDA, which must be a shock to cannabis investors, with what we believe is a superior business model to cannabis growers. (Disclosure: A director of Fincom Investment Partners is a long-time CWEB reseller).
Re-iterating our suggested target price: $5.95
We continue to suggest fair valuation for Elixinol remains one-half of CWEB's—discounted 20%. CWEB's sales are more than 2X, which equates to US$5.95.
(Source: Fincom Investment Partners)
We visited the Elixinol booth at March's Expo West (Natural Products industry biggest trade show) (our 32nd year) observing a buzz of activity; there was a continual flow of interested buyers, while management kept heading off to private meetings with Big Box retailers. We hope to see positive news flow over coming months.
Elixinol is completing its expanded production facility in Colorado, with capacity similar to Charlotte's Web. We believe production capacity and years of actual production experience is the edge for both companies in a sea of competition for "Big Box" attention.
(Source: Elixinol)
Elixinol's 2018 sales were US$26 million, up 121% annually. CWEB's were $69 million, up 74% annually. Much of Elixinol sales are in lower margin private label, which becomes a strategic advantage since neither CWEB nor CV Sciences can boast significant experience with private label, third party or bulk CBD sales. Elixinol, perhaps, has a "leg up" on branded partnerships, building the "powered by Elixinol" brand—the brand behind the brands. We believe this is a stronger competitive "moat" than just selling through fickle retailers.
The Great CBD Boom starts
From our February 4 report: "We believe, however, the CBD boom will continue, after any near-term lag—most likely towards the second half of 2019, as new, larger retailers, such as Whole Foods and the Vitamin Shoppe, and perhaps drugstore chains, etc., begin stocking product."
CVS, the largest U.S. drugstore chain, began selling CBD products on March 20. This date may represent, in the clarity of perfect hindsight, the paradigm shift into the vast reaches of mass market CBD. CVS is taking a cautious approach, starting with topicals (external balms and lotions) to avoid any FDA repercussions.
Following CVS, Walgreens announced March 27 it would start selling CBD products in 1,500 stores. No reports on supplier. We doubt any retailer will sole source, so there is room for several CBD suppliers.
We suggest the CVS news is the spear's tip, and we expect 2019 will continue to be an exciting year for CBD.
We have long argued CBD (the cannabidiols, a non-intoxicant) is a larger market—and a better investment—than cannabis. We believe CBD will become a health standard, available in multiple OTC forms and routinely sold by mass retailers, like aspirin. The OTC market for pain relief, stress and sleeping issues is massive. CBD is a perfect fit.
Wall Street is beginning to catch on:
(Source: Cowen Group)
Yes, the Canadians are coming. But not quite yet.
Many of the large Canadian cannabis companies have announced intentions to enter the U.S. CBD space. These include Canopy Growth (CGC), which has talked up a $150 million investment into U.S. hemp farming and CBD production. It is not afraid to spend money. We suspect Canopy is most likely a CBD-brand buyer once it figures out that farming is not where the big bucks are—the $5 billion cash infusion from Constellation Brands came from selling and branding, not hops and barley farming.
Tilray (TLRY) recently purchased hemp (not CBD) maker Manitoba Harvest, which sells hemp granola, oil, protein powder and milk. Making and selling CBD is an entirely different process from making granola. Nice idea, but still quite a way from CBD. Otherwise, Tilray continues its long slide back to fair value (lower) from our September 2018 call to sell TLRY/buy CBD.
Aurora Cannabis (ACB) has purchased several hemp processors, but has no actual CBD brands in the market. There was considerable chatter about partnering with Coca-Cola to produce CBD-infused drinks, but so far nothing formal. And it still has to solve the CBD-is-oil problem (see below).
Cronos (CRON) has a partnership with Ginkgo Bioworks that may (someday) produce lower-cost custom yeast strains capable of producing cannabinoids. We hope this works out—something better—CRON Q4 cannabis sales of US$4.2 million hardly seem to justify a $3.3 billion valuation. Even if Marlboro invested.
The Canadian cannabis crowd are smart people and surely see the CBD opportunity. It's real. It's happening now and it's happening all across the U.S.
We expect more CBD-related listings in the U.S., but investors can own two quality producers now. We also suggest investors recognize CBD is not software. Planting crops, building production facilities and selling into a pipeline that already has plenty of quality product is not easy. It is going to take at least two years, at the earliest, before a new player can develop into serious competition. 2019 remains opportunistic for existing CBD pure plays. Given the challenges, we think cash and stock–rich cannabis companies would be wiser to try and buy CBD producers...with their inflated stock.
Another reason to sit with CBD shares.
(Source: Fincom Investment Partners)
Stick with the Best-of-Breed
Charlotte's Web was "launched" by a 2013 CNN documentary and has been growing since. Elixinol founder/CEO Paul Benhaim has worked in the hemp industry since 1991. There are now hundreds of wannabe CBD start-ups; we avoid them because we doubt they have staying power or pricing power. Competition will increase. The vitamin and "wellness" industry attracts charlatans like moths to flame, a risky combo when combined with the penny-stock crowd. Be careful.
Other CBD producers include CV Sciences (OTC: CVSI), and we own some shares (from a low 2018 price point) in case something happens. We have been disappointed with management. Retailers complain about poor customer service; investors complain management ignores them. Quarterly sales growth has fallen off a cliff, down to just 4% in Q4. Its NASDAQ application has sat DOA now for nine months, which means there has to be something wrong? Plus, management still bizarrely insists in dividing the company, confusing investors and wasting half the presentation—as a pharmaceutical developer. It has no patent, which the U.S. Patent Office keeps denying. To us, the drug dream is presently "worthless" and only heavily promoted as some sort of ego trip.
CWEB is better known in the U.S. and Canada
Yet Elixinol shares were Exchange-approved and the IPO underwritten by a quality firm (audited by Deloitte). Since over 80% of sales are in the U.S., the company belongs in the U.S. peer group.
CWEB sales are roughly split between e-commerce and independent retailers, while about two-thirds of Elixinol's U.S. sales are in private label and bulk.
Elixinol has about $30 million in cash; CWEB $73million.
Of the pure-play CBD manufacturers, Elixinol has, by far, the largest global exposure; it is expanding operations in Japan, throughout Europe, and, of course, Australia. The company is emphatic its investments are gaining traction and will pay off handsomely. We look forward to upcoming news. It already has a strong reputation for quality in the U.S.; if combined with what could become a true global CBD brand, Elixinol should present a compelling value proposition.
Evidence of aforementioned success could also make Elixinol an irresistible target for numerous global behemoths with fear of missing out on the CBD boom.
(Source: Elixinol)
New, industry-leading products
One reason why investors should consider Elixinol as part of a sector-related portfolio: new, exciting products. Elixinol's line of water-soluble CBD is the fruit of years of research, and leads the industry. Investors may recall the early hype about cannabis/CBD-laced beverages, but soon realized the challenges working with an oil-based product. Parties involved recognize the need to develop a working solution. Water-soluble seems better. Elixinol is already there.
Elixinol has the opportunity to increase market share, both in the saturated independent retail space, plus offers a unique and compelling product for Big Box retailers.
(Source: Elixinol)
Health benefits pile up for CBD
Scientific research builds and frequent reports from CBD users maintaining a better quality of life, quality sleep, pain and inflammation relief, etc., abound
The 55+ group is an often overlooked category, with great potential: the baby boomers. Cowen reports only about 4% of seniors have tried CBD; the upside then is enormous as CBD helps wonderfully with the common age-related aches and pains. Reported results are impressive:
51% of Seniors Who Have Tried CBD Report an Improved Quality Of Life 1
"42% of the seniors surveyed said they were taking the CBD to deal with inflammation, and 40.9% to deal with chronic pain. 38.6% said they were giving CBD a try in order to deal with poor sleep quality, and 31.8% used CBD to deal with arthritis pain. And it's working.2" (1,2Source: Forbes.com February 25, 2019)
We think the older done-it-all group has less interest in spending the day "stoned," with better interest in improved health. Tens of thousands take CBD daily, even if they often do not "feel" anything. Slides like those (below) could help CBD to grow into millions of users.
We propose, beyond short-term relief, any a good chance CBD could help prevent serious disease, we'll take it. And we do. Every day. Perhaps not scientific, but suspect plenty of others will. Maybe even you:
The 81-year-old, who hasn't been identified, repeatedly refused chemotherapy and other treatments to prolong his life (pictured a CT scan of the man's tumours in July 2017)Instead, the ex-smoker, believed to be from the Stoke-on-Trent area, opted to take CBD oil for two months to tackle his lung cancer (pictured, a scan of his cancer in November 2017)
Published slides showing an 81 year-old lung cancer patient who declined chemotherapy, instead taking CBD daily for two months. The resulting tumor shrinkage is nothing short of remarkable (Source: Daily Mail 3/5/2019)
Frederick Lacy, President of Fincom Investment Partners, began as a Chicago commodity broker in 1984. In 1987 he joined Bateman Eichler, Hill Richards in Los Angeles, focusing on small to mid-cap equities, ultimately "retiring" in 2000 as a Managing Director of Investment Banking. Mr. Lacy has been involved in numerous investments, from arranging start-up capital for what became Petrohawk, which sold for $15 Billion, to mobile payments in India. Several long-time clients were founding investors of Cheniere Energy. Mr Lacy's decades in California technology includes arranging an early $13 million VC financing for "permanent ledger" software (now commonly known as "blockchain") led by top-tier fund Upfront Ventures. Other investments include 3D holographic display technology, early mobile applications, power conversion, along with multiple consumer health-related products: Canadian Glacier bottled water, Kinetin skin cream, a proprietary oxidative-stress formula, and UV purification systems. In 1989 Mr. Lacy hosted "the Venture Capitalist" which aired on (now) CNBC, and has followed the natural foods industry for 35 years.
Important Disclosure: Fincom Investment Partners and related accounts have purchased, and continue to purchase, Elixinol shares in the open market. In addition, a Director of Fincom Investment Partners has been an executive and business owner in the nutrition industry for over 35 years, developed numerous close relationships in the industry, and has a business relationship with CV Sciences and Charlotte's Web. Fincom Investment Partners has started helping Elixinol, as a consultant. We have introduced distribution relationships, key management personnel and made other suggestions, based on our long and direct experience in the retail and wholesale nutrition industry. For this we are receiving a modest monthly consulting fee. We are not insiders and our investment opinion continues to remain our own.
Fincom Investment Partners Disclaimer
Prices as of 3/28/2019. This report is for informational purposes only and is not a solicitation of any security purchase or sale. We use a 0.71 conversion rate for Australia to USD and 0.75 for Canada. Opinions expressed herein by the author are not an investment recommendation and are not meant to be relied upon in investment decisions. The information upon which this material is based was obtained from sources believed to be reliable, but has not been independently verified. Therefore, Fincom Investment Partners cannot guarantee its accuracy. Do your own due diligence. Any opinions or estimates constitute our best judgment as of the date of publication, and are subject to change without notice. We recommend investors conduct thorough investment research of their own, including detailed review of the related Companies' filings, and consult a qualified investment adviser. Fincom Investment Partners and its officers and directors own shares in the securities mentioned in this report and may buy or sell shares at any time without prior notice. Fincom Investment Partners has a consulting relationship with Elixinol.
Streetwise Reports Disclosure:
1) Frederick Lacy and Fincom Investment Partners disclosures are above.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Related Articles
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1174
|
Created
|
09/18/18
|
Type
|
Free
|
Moderators |
50 Pitt Street,
Level 6
Sydney, NSW 2000
Australia
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |